The recall affects two lots of 50 milligram strength and four lots of 100 milligram strength.
The recall is a result of the detection of N-Nitroso-N-methyl-4-aminobutyric acid, a potentially carcinogenic impurity.
The impurity was detected in one lot of an active pharmaceutical ingredient made by Hetero Labs. This active ingredient was then used by Teva to manufacturer six bulk lots of the tablets.
The bulk lots were sold to Golden State Medical Supply, which packaged these products under its own label and distributed bottles of 30, 90 and 1,000 tablets to their customers.
Read the full recall announcement here.
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.